A novel function of extraerythrocytic hemoglobin: identification of globin as a stimulant of plasminogen activator biosynthesis in human fibroblasts.
Following wounding, the surrounding fibroblasts migrate towards the clotted blood in the wounded space to form granulation tissue resulting in wound repair. One of the most abundant proteins in the wound is hemoglobin (Hb). The aim of the present study was to examine the effect of Hb on fibroblasts in producing components of the plasminogen-plasmin system which play an important role in wound healing. Human Hb A0 added to cultures of human fibroblasts elicited a dose-dependent increase in fibrinolytic activity. ELISA demonstrated an increased fibrinolytic activity due to increased urokinase-type plasminogen activator (uPA). An increase in tissue-type PA was also detected, while the type-I PA inhibitor level remained unaffected. Globin showed a similar effect, while hemin and protoporphyrin IX exerted no effect. The influence of Hb was quenched when haptoglobin was added. Although northern blot analysis revealed no difference in uPA transcripts between stimulated and non-stimulated cells, immunoprecipitation experiments confirmed an increased uPA synthesis in Hb- and globin-treated cells, suggesting that enhanced expression is achieved through translational regulation. These findings suggest a potential role for globin in modulating cellular functions during the process of wound healing.
Yoshida
E
E
Department of Physiology, Miyazaki Medical College, Japan. yetsuo@post1.miyazaki-med.ac.jp
Ohmura
S
S
Sugiki
M
M
Anai
K
K
Maruyama
M
M
D002478:Cells, Cultured / Q000187:drug effects; D005342:Fibrinolysis / Q000187:drug effects*; D005347:Fibroblasts / Q000187:drug effects* / Q000378:metabolism; D005914:Globins / Q000494:pharmacology / Q000502:physiology; D006242:Haptoglobins / Q000494:pharmacology; D006427:Hemin / Q000494:pharmacology; D006441:Hemoglobin A / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D006454:Hemoglobins / Q000502:physiology*; D006801:Humans; D009211:Myoglobin / Q000494:pharmacology; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis; D014176:Protein Biosynthesis / Q000187:drug effects; D011524:Protoporphyrins / Q000494:pharmacology; D012709:Serum Albumin / Q000494:pharmacology; D010959:Tissue Plasminogen Activator / Q000096:biosynthesis* / Q000378:metabolism; D014168:Transferrin / Q000494:pharmacology; D014568:Urokinase-Type Plasminogen Activator / Q000096:biosynthesis* / Q000378:metabolism; D014945:Wound Healing / Q000502:physiology*
D006242:Haptoglobins; D006454:Hemoglobins; D009211:Myoglobin; D017395:Plasminogen Activator Inhibitor 1; D011524:Protoporphyrins; D012709:Serum Albumin; D014168:Transferrin; C028881:hemoglobin A(0); D006427:Hemin; D005914:Globins; D006441:Hemoglobin A; C028025:protoporphyrin IX; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator